FDA Regulatory Attorney Discusses Enforcement Priorities & Whistleblower Lawsuits in Medtech Insight

In The News
November 15, 2018
Capital Insights.

Life sciences counsel Beth Weinman (Washington, D.C.) discussed U.S. Food & Drug Administration enforcement priorities and qui tam whistleblower lawsuits in a Nov. 13 article published in Medtech Insight.

Ms. Weinman, who previously served as associate chief counsel for enforcement at the FDA’s Office of Chief Counsel, addressed topics including what leads someone to file a whistleblower complaint against a medical device company, and how companies should respond if a qui tam suit is filed against it, among other issues.